Marco Armando

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/992892/publications.pdf

Version: 2024-02-01

70	3,014	201385	182168
papers	citations	27	51
		h-index	g-index

77	77	77	4033
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Psychiatric Disorders From Childhood to Adulthood in 22q11.2 Deletion Syndrome: Results From the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. American Journal of Psychiatry, 2014, 171, 627-639.	4.0	645
2	Psychotic-like experiences and correlation with distress and depressive symptoms in a community sample of adolescents and young adults. Schizophrenia Research, 2010, 119, 258-265.	1.1	235
3	Cognitive Decline Preceding the Onset of Psychosis in Patients With 22q11.2 Deletion Syndrome. JAMA Psychiatry, 2015, 72, 377.	6.0	196
4	Attachment, Neurobiology, and Mentalizing along the Psychosis Continuum. Frontiers in Human Neuroscience, 2016, 10, 406.	1.0	112
5	Clinical differences in children with autism spectrum disorder with and without food selectivity. Appetite, 2015, 92, 126-132.	1.8	96
6	The use of actigraphy in the monitoring of sleep and activity in ADHD: A meta-analysis. Sleep Medicine Reviews, 2016, 26, 9-20.	3.8	91
7	Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome. Nature Medicine, 2020, 26, 1912-1918.	15.2	90
8	Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Molecular Psychiatry, 2021, 26, 4496-4510.	4.1	87
9	Autistic Symptoms in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. Frontiers in Psychiatry, 2019, 10, 78.	1.3	86
10	Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): A systematic review of randomized clinical trials. Journal of Affective Disorders, 2014, 152-154, 39-44.	2.0	78
11	Mentalization-Based Treatment in Clinical High-Risk for Psychosis: A Rationale and Clinical Illustration. Journal of Contemporary Psychotherapy, 2016, 46, 217-225.	0.7	60
12	Neurodevelopmental and psychiatric issues in Downâ€™s syndrome. Psychiatric Genetics, 2013, 23, 95-107.	0.6	57
13	Enhanced Maternal Origin of the 22q11.2 Deletion in Velocardiofacial and DiGeorge Syndromes. American Journal of Human Genetics, 2013, 92, 439-447.	2.6	53
14	Ultra high risk status and transition to psychosis in 22q11.2 deletion syndrome. World Psychiatry, 2016, 15, 259-265.	4.8	52
15	Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 2182-2191.	0.7	51
16	Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: A comparison of prodromal psychotic symptoms and general functioning. Schizophrenia Research, 2012, 139, 151-156.	1.1	48
17	Subthreshold Psychosis in 22q11.2 Deletion Syndrome: Multisite Naturalistic Study. Schizophrenia Bulletin, 2017, 43, 1079-1089.	2.3	47
18	Twelve-month psychosis-predictive value of the ultra-high risk criteria in children and adolescents. Schizophrenia Research, 2015, 169, 186-192.	1.1	44

#	Article	IF	Citations
19	Longitudinal comparison between male and female preschool children with autism spectrum disorder. Journal of Autism and Developmental Disorders, 2015, 45, 2046-2055.	1.7	43
20	Complete Sequence of the 22q11.2 Allele in 1,053 Subjects with 22q11.2 Deletion Syndrome Reveals Modifiers of Conotruncal Heart Defects. American Journal of Human Genetics, 2020, 106, 26-40.	2.6	42
21	The use of actigraphy in the monitoring of methylphenidate versus placebo in ADHD: a meta-analysis. ADHD Attention Deficit and Hyperactivity Disorders, 2014, 6, 49-58.	1.7	41
22	Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. Nature Communications, 2018, 9, 2265.	5.8	38
23	Prevalence of Non-Affective Psychoses in Individuals with Autism Spectrum Disorders: A Systematic Review. Journal of Clinical Medicine, 2019, 8, 1304.	1.0	34
24	Self-Esteem Evaluation in Children and Adolescents Suffering from ADHD. Clinical Practice and Epidemiology in Mental Health, 2013, 9, 96-102.	0.6	34
25	Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects. American Journal of Medical Genetics, Part A, 2018, 176, 2172-2181.	0.7	33
26	Psychotic experience subtypes, poor mental health status and helpâ€seeking behaviour in a community sample of young adults. Microbial Biotechnology, 2012, 6, 300-308.	0.9	32
27	Adolescence is the starting point of sex-dichotomous COMT genetic effects. Translational Psychiatry, 2017, 7, e1141-e1141.	2.4	32
28	Proactive and reactive control of movement are differently affected in Attention Deficit Hyperactivity Disorder children. Research in Developmental Disabilities, 2013, 34, 3104-3111.	1.2	31
29	PEMapper and PECaller provide a simplified approach to whole-genome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1923-E1932.	3.3	31
30	Coping Strategies Mediate the Effect of Stressful Life Events on Schizotypal Traits and Psychotic Symptoms in 22q11.2 Deletion Syndrome. Schizophrenia Bulletin, 2018, 44, S525-S535.	2.3	29
31	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. Frontiers in Psychiatry, 2019, 10, 345.	1.3	29
32	Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. European Child and Adolescent Psychiatry, 2016, 25, 1091-1102.	2.8	26
33	Psychosocial interventions for very early and early-onset schizophrenia. Current Opinion in Psychiatry, 2015, 28, 312-323.	3.1	25
34	Clinical presentation of Attenuated Psychosis Syndrome in children and adolescents: Is there an age effect?. Psychiatry Research, 2017, 252, 169-174.	1.7	22
35	Paediatric Non-Alcoholic Fatty Liver Disease: Impact on Patients and Mothersâ€™ Quality of Life. Hepatitis Monthly, 2013, 13, e7871.	0.1	19
36	Is it still correct to differentiate between early and very early onset psychosis?. Schizophrenia Research, 2016, 170, 211-216.	1.1	19

#	Article	IF	Citations
37	Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome. Schizophrenia Research, 2019, 204, 320-325.	1.1	19
38	Prevalence, course and psychosis-predictive value of negative symptoms in 22q11.2 deletion syndrome. Schizophrenia Research, 2019, 206, 386-393.	1.1	19
39	Prevalence of Psychotic-like Experiences in Young Adults With Social Anxiety Disorder and Correlation With Affective Dysregulation. Journal of Nervous and Mental Disease, 2013, 201, 1053-1059.	0.5	18
40	Associations between schizotypal personality features, mentalizing difficulties and thought problems in a sample of community adolescents. Microbial Biotechnology, 2021, 15, 705-715.	0.9	16
41	The influence of Generalized Anxiety Disorder on Executive Functions in children with ADHD. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 349-357.	1.8	15
42	Pituitary dysmaturation affects psychopathology and neurodevelopment in 22q11.2 Deletion Syndrome. Psychoneuroendocrinology, 2020, 113, 104540.	1.3	15
43	All that glitters is not gold: prevalence and relevance of psychoticâ€like experiences in clinical sample of children and adolescents aged 8â€“17 years old. Microbial Biotechnology, 2018, 12, 702-707.	0.9	14
44	An Overview of Recent Findings on Social Anxiety Disorder in Adolescents and Young Adults at Clinical High Risk for Psychosis. Brain Sciences, 2017, 7, 127.	1.1	13
45	Cortical morphology development in patients with 22q11.2 deletion syndrome at ultra-high risk of psychosis. Psychological Medicine, 2018, 48, 2375-2383.	2.7	13
46	Clinical high risk for psychosis model in children and adolescents: a joint position statement of ESCAP Clinical Division and Research Academy. European Child and Adolescent Psychiatry, 2020, 29, 413-416.	2.8	13
47	No age effect in the prevalence and clinical significance of ultra-high risk symptoms and criteria for psychosis in 22q11 deletion syndrome: Confirmation of the genetically driven risk for psychosis?. PLoS ONE, 2017, 12, e0174797.	1.1	12
48	A Mentalization-Informed Staging Approach to Clinical High Risk for Psychosis. Frontiers in Psychiatry, 2019, 10, 385.	1.3	12
49	A normative chart for cognitive development in a genetically selected population. Neuropsychopharmacology, 2022, 47, 1379-1386.	2.8	12
50	Clinical picture and treatment implication in a child with Capgras syndrome: a case report. Journal of Medical Case Reports, 2012, 6, 406.	0.4	10
51	Association Between Parental Anxiety and Depression Level and Psychopathological Symptoms in Offspring With 22q11.2 Deletion Syndrome. Frontiers in Psychiatry, 2020, 11, 646.	1.3	10
52	COMT Implication in Cognitive and Psychiatric Symptoms in Chromosome 22q11 Microdeletion Syndrome: A Selective Review. CNS and Neurological Disorders - Drug Targets, 2012, 11, 273-281.	0.8	10
53	No evidence for the presence of genetic variants predisposing to psychotic disorders on the non-deleted 22q11.2 allele of VCFS patients. Translational Psychiatry, 2017, 7, e1039-e1039.	2.4	9
54	Favorable effects of omega-3 polyunsaturated fatty acids in attentional control and conversion rate to psychosis in 22q11.2 deletion syndrome. Neuropharmacology, 2020, 168, 107995.	2.0	9

#	Article	IF	Citations
55	Schizophrenia Spectrum Disorders and Autism Spectrum Disorder. , 2016, , 51-66.		9
56	Prevalence and treatment of psychiatric disorders other than psychosis in children and adolescents with 22q11DS: Examining associations with social and role functioning. Psychiatry Research, 2017, 254, 238-243.	1.7	8
57	Prevalence and Clinical Significance of Symptoms at Ultra High Risk for Psychosis in Children and Adolescents with Obsessiveâ€“Compulsive Disorder: Is There an Association with Global, Role, and Social Functioning?. Brain Sciences, 2018, 8, 181.	1.1	8
58	Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing. ELife, 2021, 10, .	2.8	7
59	Mental uneasiness, perceived stress and help-seeking in a non-resident university student sample (in) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	6
60	Indicated prevention with longâ€chain polyunsaturated omegaâ€3 fatty acids in patients with 22q11<scp>DS</scp> genetically at high risk for psychosis. Protocol of a randomized, doubleâ€blind, placeboâ€controlled treatment trial. Microbial Biotechnology, 2016, 10, 390-396.	0.9	6
61	Antipsychotics Do Not Influence Neurological Soft Signs in Children and Adolescents at Ultra-High Risk for Psychosis. Journal of Psychiatric Practice, 2019, 25, 186-191.	0.3	4
62	Visual perception skills: a comparison between patients with <scp>N</scp>oonan syndrome and 22q11.2 deletion syndrome. Genes, Brain and Behavior, 2017, 16, 627-634.	1.1	3
63	Borderline cognitive level in a family with Bazexâ€ÐuprÃ©â€Christol syndrome. American Journal of Medical Genetics, Part A, 2015, 167, 1637-1643.	0.7	2
64	Dopamine dysfunction in 22q11 deletion syndrome. Psychiatric Genetics, 2016, 26, 187-192.	0.6	2
65	Clinical high risk for psychosis paradigm for CAP: do not throw the baby out with the bathwater. European Child and Adolescent Psychiatry, 2020, , 1.	2.8	2
66	Enhanced Maternal Origin of the 22q11.2 Deletion in Velocardiofacial and DiGeorge Syndromes. American Journal of Human Genetics, 2013, 92, 637.	2.6	1
67	22q11 microdeletion syndrome and ultraâ€high risk for psychosis: The role of neurological soft signs as an independent marker of vulnerability for psychosis. Microbial Biotechnology, 2019, 13, 1191-1198.	0.9	1
68	Sustain and reinforce transition from child to adult mental health care in Switzerland: study protocol. Swiss Archives of Neurology, Psychiatry and Psychotherapy, 0, , .	0.4	1
69	22q11.2 deletion syndrome. , 2020, , 143-164.		0
70	Schizofrenia ad esordio in etÃ evolutiva: aspetti clinici e interventi possibili. Quaderni Di Psicoterapia Cognitiva, 2016, , 25-41.	0.1	0